Cell Source Inc
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of ly… Read more
Cell Source Inc (CLCS) - Net Assets
Latest net assets as of September 2024: $-18.94 Million USD
Based on the latest financial reports, Cell Source Inc (CLCS) has net assets worth $-18.94 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($264.66K) and total liabilities ($19.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-18.94 Million |
| % of Total Assets | -7156.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16737.13 |
Cell Source Inc - Net Assets Trend (2012–2023)
This chart illustrates how Cell Source Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cell Source Inc (2012–2023)
The table below shows the annual net assets of Cell Source Inc from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-15.61 Million | -23.57% |
| 2022-12-31 | $-12.63 Million | -28.57% |
| 2021-12-31 | $-9.83 Million | -23.64% |
| 2020-12-31 | $-7.95 Million | -38.41% |
| 2019-12-31 | $-5.74 Million | -25.99% |
| 2018-12-31 | $-4.56 Million | 0.00% |
| 2017-12-31 | $-4.56 Million | +27.00% |
| 2016-12-31 | $-6.24 Million | -8.42% |
| 2015-12-31 | $-5.76 Million | -52.18% |
| 2014-12-31 | $-3.78 Million | -33507.45% |
| 2013-12-31 | $11.33K | -33.19% |
| 2012-12-31 | $16.95K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cell Source Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4166234100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $39.83K | % |
| Other Comprehensive Income | $-39.83K | % |
| Other Components | $26.06 Million | % |
| Total Equity | $-15.61 Million | 100.00% |
Cell Source Inc Competitors by Market Cap
The table below lists competitors of Cell Source Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inswave Systems Co., Ltd.
KQ:450520
|
$10.77 Million |
|
Choice Development Inc
TW:9929
|
$10.77 Million |
|
Barrister Energy LLC
PINK:CJAX
|
$10.78 Million |
|
TVI Pacific Inc
PINK:TVIPF
|
$10.78 Million |
|
EURO MANGANESE CDI/1
F:E06A
|
$10.77 Million |
|
Hammer Metals Limited
F:6HM
|
$10.76 Million |
|
Pinnacle Bancshares Inc
PINK:PCLB
|
$10.76 Million |
|
Procorp S.A.B. de C.V
MX:PROCORPB
|
$10.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cell Source Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -12,633,895 to -15,611,543, a change of -2,977,648.
- Net loss of 5,167,748 reduced equity.
- Dividend payments of 1,228,685,000,000 reduced retained earnings.
- New share issuances of 799,918 increased equity.
- Other comprehensive income decreased equity by 39,831.
- Other factors increased equity by 1,228,686,430,013.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.17 Million | -33.1% |
| Dividends Paid | $1.23 Trillion | -7870362.33% |
| Share Issuances | $799.92K | +5.12% |
| Other Comprehensive Income | $-39.83K | -0.26% |
| Other Changes | $1.23 Trillion | +7870371.49% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cell Source Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $1.40 | $0.36 | x |
| 2013-12-31 | $0.00 | $0.36 | x |
| 2014-12-31 | $-0.17 | $0.36 | x |
| 2015-12-31 | $-0.22 | $0.36 | x |
| 2016-12-31 | $-0.24 | $0.36 | x |
| 2017-12-31 | $-0.18 | $0.36 | x |
| 2018-12-31 | $-0.17 | $0.36 | x |
| 2019-12-31 | $-0.20 | $0.36 | x |
| 2020-12-31 | $-0.27 | $0.36 | x |
| 2021-12-31 | $-0.30 | $0.36 | x |
| 2022-12-31 | $-0.36 | $0.36 | x |
| 2023-12-31 | $-0.41 | $0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cell Source Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-19.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -9.80% | 0.00% | 0.00x | 1.30x | $-3.36K |
| 2013 | -226.27% | 0.00% | 0.00x | 1.65x | $-26.76K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.68 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.93 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-343.49K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.63 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.63 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.21 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.70 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.85 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.90 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.61 Million |
Industry Comparison
This section compares Cell Source Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cell Source Inc (CLCS) | $-18.94 Million | -9.80% | N/A | $10.77 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |